OXFORD GLOBAL

4th Annual Cell & Gene Therapy Congress

25-26 October 2018 | London, UK

Day 1
Stream 1 – Cell & Gene Therapy Development and Clinical Trials

- Recent Clinical advances in:
  - *Off-The-Shelf Natural Killer Cells*
  - *Targeting Solid Tumours*
  - *CAR T Therapies For Head & Neck Cancer*
  - *Rare & Severe Childhood Diseases*
  - *Chemotherapy & Radiation Exposure*
  - *Opthalmological Disease*
- Future challenges with the development of gene and advanced therapies
- Clinical safety testing models for effective and commercially successful CAR and TCR cell immunotherapies
- Patient focussed aspects to clinical development and clinical trials
- **Panel discussion**: Future challenges with the development of gene and advanced therapies

Day 1
Stream 2 – Cell and Gene Therapy Bioprocessing and Manufacturing Strategies

- CAR T Including:
  - Allogenic CAR T Performance in Manufacturing & Industrialisation
  - CAR T Process Development & Manufacturing Considerations
  - Development of Gamma-Delta Cell Therapy
- Implementation of affordable And Scalable Manufacturing Strategies
- Quality Assurance Through the Entire Supply Chain
- Regulatory Considerations for Expedited Quality Development And Bioprocessing
- Viral Safety By Design For Cell & Gene Therapy Products
- Bypassing Genome Editing Tools
- Comparability For Viral Vectors

Day 2 Stream 1
Part 1 – Cell and Gene Therapy Manufacturing

- **Workshop:** Cell and Gene Therapy Manufacturing
- Scale-Up Solutions And Automation In Manufacturing of Cell Therapies

Part 2 – Commercialising Cell & Gene Treatments

- Innovative Pricing Strategies For ATMPs
- Business Transformation And Partnering Strategies To Accelerate Commercialisation
- Lessons for CAR T Commercialisation from: Bluebird Bio And Celgene
- How Do We Ensure Affordability And Accessibility To Patients
- Regulatory Challenges For The Development & Approval Of Novel Cell & Gene Therapies
- Futures Of CAR T Therapies
- **Panel Discussion:** Reimbursement And Pricing Strategies for Cell And Gene Therapies

Benefits to Attending

✓ **Hear from pioneers and leaders in the cell and gene therapy field.** 2018 Attendees include: Senior Vice President, GSK; Senior Vice President, Cellectis; Vice President, Janssen; Director, Biogen; and Vice President, Bluebird Bio

✓ **Discuss collaborative solutions to cell and gene therapy development and commercialisation challenges.** This event brings together innovators addressing current trends in novel therapeutic areas, Important regulatory considerations and critical reimbursement and pricing strategies

✓ **Discover the latest innovations in cell therapy bioprocessing and manufacturing.** Case studies include CAR T cell immunotherapies, the application of genome editing technology, novel vector systems and viral safety for gene therapy and scalable manufacturing strategies

✓ **Unparalleled networking opportunities**. The two-day congress offers dedicated networking breaks creating an interactive platform for scientific discussions and 1-2-1 meetings. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion

✓ **A high-quality programme devised with the help of our esteemed advisory board.** Presentations covering updates in upstream and downstream processing, recent advances in CAR T cell therapies and the future challenges for Advanced Therapeutic Medicinal Products

✓ This event is part of our flagship **Cell Series**, which also includes our **7th Annual Cell Culture & Bioprocessing, 5th Annual Stem Cell Congress** and inaugural **Biobanking Congress**

2018 Speakers Include:

Axel Hoos
GSK

David Sourdive
Cellectis

Peter Olagunju
Bluebird Bio

Meet Senior Decision Makers

Over 300 VPs, Directors & Senior Managers from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job functions include:

Cell Therapy	Process Development	Stem Cell Therapy
Gene Therapy	Biotherapeutics	Cell Therapy Manufacture
Regulatory Affairs	Commercialisation	Regenerative Medicine

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Cell Activation	CRISPR, TALEN, RNAi	Assay Development
Flow Cytometry	Tissue Printing	Cryopreservation
Separation Reagents	Cell Storage	Cell Line Development

For booking details & registration fees please visit:
https://www.oxfordglobal.co.uk/celltherapy-congress/

COMPLIMENTARY PRE-CONGRESS WEBINARS

Strategies In CAR T Development And Targeting –30th August 2018, 10am GMT(UK). 11am CET(Europe)
Led by:
Katrien Reynders, Programme Director, Celyad
Peggy Sotiropoulou, Research & Development Manager, Celyad

COMPLIMENTARY PRE-CONGRESS Q&As

Outlook of Cell & Gene Therapies in 2018
Michael Kalos, Senior Vice President, Immunooncology & Oncology Cellular Therapies, Janssen

CAR T Therapies – Targeting Unmet Medical Needs
Paul Rennert, President & Chief Executive Officer, Aleta Biotherapeutics

Reserved and Confirmed Cell & Gene Therapy 2018 Speakers:

- Axel Hoos, Senior Vice President & Oncology Therapeutic Area Head, GSK
- Michael Kalos, Vice President, Immunooncology and Oncology Cellular Therapies, Janssen
- David Sourdive, Executive Vice President, Technical Operations, Cellectis
- Nebojsa Milovic, Vice President, Cell & Gene Therapy Pharmaceutical Sciences, Takeda
- Stefanos Theoharis, Senior Vice President, Corporate Development, Cell Medica
- Adrien Lemoine, Senior Vice President, Business Development & Alliance Management, Orchard Therapeutics
- Suyash Prasad, Senior Vice President & Chief Medical Officer, Audentes Therapeutics
- Lothar Germeroth, Senior Vice President, Juno Therapeutics
- Peter Olagunju, Vice President, Patient Operations & Lentiglobin Program Leader, Bluebird Bio
- Nina Kotsopoulou, Vice President, Process Development, Autolus
- Aniz Girach, Chief Medical Officer, Nightstar Tx
- Jens Hasskarl, Senior Medical Director, Clinical R&D & Program Lead, CRP – Juno CAR T Therapy, Celgene
- Diane Wilkinson, Director of Regulatory & CMC, Biogen
- Jerome Zeldis, Chief Medical Officer & President of Clinical Development, Sorrento Therapeutics
- Ram Mandalam, President & Chief Executive Officer, Cellerant
- Paul Rennert, President & Chief Executive Officer, Aleta Biotherapeutics
- Mark Plavsic, Chief Technical Officer, Lysogene
- Keith Foster, Chief Scientific Officer, Sutura Therapeutics and Professor of Translational Medicine, University of Reading
- John Maher, Chief Science Officer, Leucid Therapeutics and Senior Lecturer of Immunology, King's College London
- Owain Millington, Head of New Product Development, TC BioPharm
- Jennifer Chow, Global Commercial CAR T Lead, Celgene
- Lawrence Thompson, Principal Scientist & Group Leader, Pfizer
- Sarah Snykers, Quality Control Manager, Celyad
- Ricardo Baptista, Lead Scientist, Process Development
- Katy Rezvani, Chief of Cellular Therapy, Medical Director of GMP Facility, MD Anderson Center
- Panos Kefalas, Head of Health Economics & Market Access, Cell & Gene Therapy Catapult
- Magda Papadaki, Head of Manufacturing & Innovation, Association of the British Pharmaceutical Industry
- Paolo Morgese, Director of EU Market Access & Member Relations, Alliance for Regenerative Medicine

2018 Cell Series Sponsors

Gold Sponsor

MaxCyte®

Bronze Sponsor:

PROzyme Advancing Glycosciences

BPES BIOPROCESS ENGINEERING SERVICES LTD

sartorius

Networking and Programme Sponsors:

PEPROTECH OUR SUPPORT, YOUR DISCOVERY

MERCK

rssl science with service

BIOTHERAPY macopharma DESIGNED FOR LIFE

OXFORD GENETICS BIOLOGY ENGINEERED

Tissue Solutions Working with you. For you.

Solentim Clarity in Cell Line Development

eppendorf

BD

Ziath

Roche

4rd Annual Cell and Gene Therapy Congress
Day One – 25th October 2018

	4th Annual Cell & Gene Therapy Congress	
07.30 – 08.20	**Registration**	
08.20 – 08.25	**Oxford Global's Welcome Address**	
08.25 – 08.30	**Chairperson's Opening Address:**	
08.30 – 09.00	**Keynote Address:** **The Next Frontier – An Overview Of Living Therapies In Oncology** **Michael Kalos, Vice President, Immunooncology & Oncology Cellular Therapies, Janssen**	
	Cell & Gene Therapy Development and Clinical Trials	**Cell and Gene Therapy Bioprocessing and Manufacturing Strategies**
	Stream Chair: To Be Confirmed	**Stream Chair: Maria Rende, Senior Biotherapy Sales Specialist, Macopharma**
09.00 – 09.30	**Stream Keynote Address:** **Future Challenges With The Development Of Gene And Advanced Therapies** **Axel Hoos, Senior Vice President, Therapeutic Area Head of Oncology, GSK**	**Stream Keynote Address:** **Allogenic CAR T Performance In Manufacturing And Industrialisation** **David Sourdive, Executive Vice President, Technical Operations, Cellectis**
09.30 – 10.00	**Solution Provider Presentation** **For Sponsorship Opportunities please contact sponsorship@oxfordglobal.co.uk**	**Solution Provider Presentation** OXFORD GENETICS BIOLOGY ENGINEERED
10.00 – 11.20	**Morning Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions**	
11.20 – 11.50	**Predicting Long Term Risk Benefit Of CAR T Cell Therapies** **Jens Hasskarl, Senior Medical Director, Clinical Research & Development & Program Lead CRP – Juno CAR T Therapy, Celgene**	**Regulatory Considerations For Expedited Quality Development & Bioprocessing** **Diane Wilkinson, Director, Regulatory CMC, Biogen**
11.50 – 12.20	**CAR T Anti-CD38 For Multiple Myeloma And Anti-CEA For Solid Tumours** **Jerome Zeldis, Chief Medical Officer & President of Clinical Development, Sorrento Therapeutics**	**Novel Process Technology For The Accelerated Manufacture Of CAR T Therapies** **Lothar Germeroth, Senior Vice President, Juno Therapeutics**
12.20 – 12.50	**Solution Provider Presentation** **For Sponsorship Opportunities Please Contact sponsorship@oxfordglobal.co.uk**	**Solution Provider Presentation** **For Sponsorship Opportunities Please Contact sponsorship@oxfordglobal.co.uk**
12.50 – 13.50	**Lunch, Poster Presentation Sessions**	
13.50 – 14.20	**Panel Discussion – Future Challenges With The Development Of Gene And Advanced Therapies** Invited Moderator: **Axel Hoos, GSK** **Invited Panelists:** **Katy Rezvani, Chief of Cellular Therapy, MD Anderson Center** **John Maher, Chief Scientific Officer, Leucid Bio & Senior Lecturer in Immunology, King's College London** **Keith Foster, Chief Science Officer, Sutura and Associate Professor In Translational Medicine, University of Reading**	**Viral Safety by Design for Cell And Gene Therapy Products** • Product safety an important critical quality attribute of medicinal products. • Adventitious agents represent an undesired impurity and as such they impact product and patient safety. • ways to mitigate the risk of adventitious agents in the manufacture of cellular and gene therapy product, • looking at various interconnected links throughout the manufacturing process from starting materials and suppliers of raw materials to fill and finish. **Mark Plavsic, Chief Technical Officer, Lysogene**

4th Annual Cell and Gene Therapy Congress
Day One – 25th October 2017

	4th Annual Cell & Gene Therapy Congress	
14.20 – 14.50	**Gene Therapy For Rare Diseases: Moving From Pre-Clinical Proof Of Concept To Clinical Trials** • Approach to Designing Clinical Trials for Rare, Severe, Genetic Disease • Informing Regulatory Strategy • Clinical data from the X-linked Myotubular Myopathy and Crigler Najjar Programs **Suyash Prasad, Chief Medical Officer & President, Audentes Therapeutics**	**NKT Cells For The Development Of Off-The-Shelf CAR Products That Do Not Require Gene Editing** • Natural Killer T-cells (NKT cells) are a highly-active subpopulation of T-cells with unique characteristics that render them ideal to off-the-shelf applications using chimeric antigen receptors (CARs). In addition, they are resistant to suppressive cells in the tumour micro-environment. • NKT cells are invariant, targeting pathogen-specific glycolipids that are not present on human cells and do not therefore cause GvHD. They can therefore be used in allogeneic settings without the need for gene editing (CRISPR/TALEN/other) to remove their T-cell receptor. This reduces the complexity and cost of manufacturing CAR-NKT products and ensures all patients receive a consistent and efficacious product. • Cell Medica is developing multiple products based on the CAR-NKT platform for indications of high unmet medical need, in partnership with the Baylor College of Medicine. The products are further engineered to secrete cytokines that further enhance their persistence and activity in solid tumours. **Stefanos Theoharis, Senior Vice President, Corporate Development, Cell Medica**
14.50 – 15.20	**Solution Provider Presentation** **For Sponsorship Opportunities Please Contact sponsorship@oxfordglobal.co.uk**	**Solution Provider Presentation** **For Sponsorship Opportunities Please Contact sponsorship@oxfordglobal.co.uk**
15.20 – 16.20	**Afternoon Coffee & Refreshments, One To One Meetings x3, Poster Presentation Sessions**	
16.20 – 16.50	**Optimising Delivery Of Antisense Gene Medicines** • Improving Therapeutic Outcomes • Decreasing Potential Toxicities • Improving Cost of Goods **Keith Foster, Chief Science Officer, Sutura Therapeutics and Associate Professor In Translational Medicine, University of Reading**	**CAR T Process Development And Manufacturing Considerations (TBC)** • CAR/TCR Approaches • Assay Development • Comparability **Nina Kotsopoulou, Director, Process Development, Autolus**
16.50 – 17.20	**Allogeneic MPC Therapy For The Treatment of Severe Neutropenia Following Myelosuppressive Chemotherapy Or Radiation Exposure** **Ram Mandalam, President & CEO, Cellerant**	**Development Of Gamma-Delta CAR T Cell Therapies** **Owain Millington, Head of New Product Development, TC BioPharm**
17.20 – 17.50	**T4 Immunotherapy Of Head And Neck Cancer Using Pan-ErbB Retargeted CAR T Cells** • A CAR has been engineered using a promiscuous ligand that engages 8 distinct ErbB dimer species • Anti-tumour activity has been demonstrated in several pre-clinical solid tumour models • Phase 1 evaluation is ongoing in patients with head and neck cancer, using intra-tumoural delivery and phased dose escalation to mitigate risk **John Maher, Chief Scientific Officer, Leucid Bio & Senior Lecturer in Immunology, King's College London**	**Quality Control and Assurance Throughout The Full Supply Chain Of Autologous CAR-T Products** • Quality Control throughout manufacturing of autologous CAR-T (start + raw material, process, QC testing, product delivery) • -GMP, ICH, USP & PhEur guidance **Sarah Snykers, Quality Control Manager, Celyad**

4th Annual Cell and Gene Therapy Congress
Day One – 25th October 2017

	4th Annual Cell & Gene Therapy Congress	
17.50 – 18.20	**First-In-Human Trial Of Off-The-Shelf Cord Blood Derived CAR-Engineered NK Cells For The Treatment Of Cancer** • Use of human cord blood to produce NK cells engineered with a CAR to redirect specificity and enhance persistence • Expression of CARs with novel signaling domains in NK cells • Data from the first-in-human Phase I/II study of CAR-engineered NK cells to target relapsed/refractory lymphoid malignancies **Katy Rezvani, Chief of Cellular Therapy, MD Anderson Cancer Center**	**Comparability For Viral Vectors** **Lawrence Thompson, Principal Scientist, Pfizer**
18.20 – 18.50	**CAR19 T Cells Carrying Multi-Antigen Targeting Payloads: Tackling Persistence And Tumor Antigen Heterogeneity For The Treatment Of Diverse Tumors** • IMPACTtm technology enables robust and modular antigen targeting using a single CAR • Multiple antigens are attacked simultaneous, with low pM activity • Technology addresses critical issues of antigen loss and antigen heterogeneity **Paul Rennert, President & Chief Executive Officer, Aleta Biotherapeutics**	*Delegates are invited to attend the collocated presentations*
18.50 – 19.20	**Innovative Opthalmology Endpoints** • Novel endpoints in retinal trials • Regulatory perspective of these endpoints • Future endpoints in gene therapy trials **Aniz Girach, Chief Medical Officer, Nightstar Tx**	*Delegates are invited to attend the collocated presentations*
19.20 – 19.50	**Networking Drinks & End Of Day One**	

4th Annual Cell and Gene Therapy Congress
Day Two – 26th October 2017

	4th Annual Cell & Gene Therapy Congress
08.30 – 09.30	**One Hour Workshop And Breakfast – Cell & Gene Therapy Manufacturing** • Two Presentations from the leading representatives in cell & gene therapy **Operational Excellence in Cell & Gene Therapy** **Frank Thielmann, PMO & Operational Excellence Leader, Novartis** **Panel Discussion – Cost-Effectiveness in Cell & Gene Therapy Manufacture** • Cost of Goods • When scaling up/out • automation **Moderator: David Sourdive, Executive Vice President, Technical Operations, Cellectis** **Invited Panellists:** **Nebojsa Milovic, Vice President of Cell Therapy Pharmaceutical Science, Takeda** **Ricardo Baptista, Lead Scientist, Process Development, Cell & Gene Therapy Catapult**
	Cell and Gene Therapy Manufacturing
09.30 – 10.00	**Solution Provider Presentation** **For Sponsorship Opportunities Please Contact** **sponsorship@oxfordglobal.co.uk**
10.00 – 11.00	**Morning Coffee & Refreshments, One to One Meetings x3, Poster Presentation Sessions**
11.00 – 11.30	**CMC For Cell Therapies – Scale-Up Solutions And Automation In Manufacturing** **Nebojsa Milovic, Vice President of Cell Therapy Pharmaceutical Science, Takeda**
11.30 – 12.00	**Scale-Up Manufacture Of Allogenic Cell Therapies Derived From Pluripotent Stem Cells** **Ricardo Baptista, Lead Scientist, Process Development, Cell & Gene Therapy Catapult**
	Commercialising Cell & Gene Treatments
12.00 – 12.30	**Innovative Pricing Schemes for ATMP** • The presentation will cover the key considerations from both the payer and the manufacturer perspective in optimizing pricing and access • It will concentrate on the specific challenges ATMPs present in the context of reimbursement and strategies to mitigate commercial risk **Panos Kefalas, Head of Health Economics & Market Access, Cell & Gene Therapy Catapult**
12.00 – 12.30	**Solution Provider Presentation** **For Sponsorship Opportunities Please Contact** **sponsorship@oxfordglobal.co.uk**
12.30 – 13.30	**Lunch, Poster Presentation Sessions**

4th Annual Cell and Gene Therapy Congress
Day Two – 26th October 2017

	4th Annual Cell & Gene Therapy Congress
13.30 – 14.00	**Business Transformation And Partnering Strategies To Accelerate Commercialisation** • Developing a predictable route to market and patient access for CAR T therapies: Understanding Production, Clinical Trial and Value Assessment Interfaces. • Using partnerships between developers, regulators and health systems to accelerate CAR T and new immunotherapy commercialization pathways. **Magda Papadaki, Head of Manufacturing & Innovation, Association of the British Pharmaceutical Industry**
14.00 – 14.30	**Lessons in Commercialization of Cell And Gene Therapies** • Lessons in Commercialization of Cell and Gene Therapies • Commercialization scorecard • The importance of a streamlined patient centric approach • Addressing Cost of Goods **Peter Olagunju, Vice President, Patient Operations & *Lentiglobin* Programme Leader, Bluebird Bio**
14.30 – 15.00	**Panel Discussion: Reimbursement And Pricing Strategies For Cell And Gene Therapies** **Moderator:** Invitation to: **Confirmed Panelists:** **Magda Papadaki, Head of Manufacturing & Innovation, The Association of the British Pharmaceutical Industry** **Panos Kefalas, Head of Health Economics & Market Access, Cell & Gene Therapy Catapult UK** **Paolo Morgese, Director of EU Market Access & Member Relations, Alliance for Regenerative Medicine** Invitation to: **Peter Olagunju, Vice President, Patient Operations & Lentiglobin Programme Leader, Bluebird Bio** **Adrien Lemoine, Senior Vice President, Business Development & Alliance Management, Orchard Therapeutics**
15.00 – 15.30	**Afternoon Coffee & Refreshments, Poster Presentation Sessions**
15.30 – 16.00	**Insights Into CAR T Commercialisation** **Jennifer Chow, Global Commercial CAR T Lead, Celgene**
16.00 – 16.30	**Academic And Manufacturing Partnerships In Cell And Gene Therapy** • Creating a discovery and clinical development engine through academic alliances • Partnering with CDMOs to access expertise and manufacturing capacity **Adrien Lemoine, Senior Vice President, Business Development & Alliance Management, Orchard Therapeutics**
16.30 – 17.00	**Areas of Strategic Importance for Cell & Gene Therapy: Going Forward** **Paolo Morgese, Director of Market Access & Member Relations, Alliance for Regenerative Medicine**
17.00	**End of Conference**

4th Annual Cell and Gene Therapy Congress

25—26 October 2018 | Novotel London West Hotel, London, UK
www.oxfordglobal.co.uk/celltherapy-congress

HOW TO REGISTER:
FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: marketing@oxfordglobal.co.uk

Delegate Details

Please complete fully and clearly. Please photocopy for additional delegates

Title:____ Forename:_____ Surname:_____

Job Title:_____

Company/Organisation:_____

Email:_____

Address:_____

_____

Postcode: _____

Country: _____

Direct Telephone _____ Direct Fax: _____

Mobile: _____ Switchboard: _____

Signature: _____

Date: _____

Registration Fees

I would like to attend: (Please tick as appropriate)

Industry Delegates (Biopharma, Pharma or Biotech Companies)

☐ Congress	£899 plus VAT
1 day pass	£599 plus VAT
☐ Day 1	
☐ Day 2	

Academic Delegates

☐ Congress	£520 plus VAT
1 day pass	£320 plus VAT
☐ Day 1	
☐ Day 2	

Vendor Delegates
(CROs, Consultants, Technology and Service Providers)

☐ Congress Only	£1750 plus VAT
1 day pass	£999 plus VAT
☐ Day 1	
☐ Day 2	
☐ Poster Presentation	£250 plus VAT

PROMOTIONAL LITERATURE DISTRIBUTION

☐ Distribution of your company's promotional literature to all conference attendees £999 plus VAT

Terms & Conditions of Booking

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:

Delegate Booking Fee
The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online.
Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.

Poster Presentations
Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size.

Cancellation and Curtailment
Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.

More than 6 months prior	35% cancellation fee / 65% refund
Between 6 and 3 months prior	75% cancellation fee / 25% refund
Less than 3 months prior to the event	Full cancellation fee / No refund

Data Protection
The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/her personal and company information on the terms set out herein.

Miscellaneous
This Agreement may not be transferred or assigned by either the Delegate or the Delegate's Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate's Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded. For promotional purposes, there may be professional photography and video production taking place during the conference. Delegates who do not wish to be filmed or recorded should advise the organisers by email to operations@oxfordglobal.co.uk, prior to the event.

☐ **I agree to the above Terms and Conditions**

Documentation

I cannot attend but would like to purchase access to the following:

☐ Access to the online conference presentations £499 plus VAT

VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

How to Pay (choose one of the following payment options)

Number of delegates:

Industry del(s) ☐ Academic dels(s) ☐ Vendor dels(s) ☐

☐ **Special Offer: 3 for 2**
Offer is only valid on the congress and for those registering at Industry or Academic rates

CREDIT CARD: ☐Visa ☐MasterCard ☐Maestro ☐Amex

Credit Card Number:
☐☐☐☐ ☐☐☐☐ ☐☐☐☐ ☐☐☐☐

Valid from: ☐☐/☐☐ Expiry Date: ☐☐/☐☐

Security code: ☐☐☐☐

Cardholders name: _____

Signature: _____ Date: _____

☐ **PLEASE INVOICE ME:**

Invoice Address (if different from above)_____

_____

*Please note there is a £50 plus VAT handling charge for payment via invoice